(Q35542453)

8 August 2017

title

Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin (English)

1 reference

8 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1034/J.1600-0560.2003.00113.X

13 March 2024

author name string

Rachel Toney

2

1 reference

8 August 2017

Joseph C. English

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507411

13 March 2024

James W. Patterson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507411

13 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14507411

13 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1034%2Fj.1600-0560.2003.00113.x

1 reference

https://api.crossref.org/works/10.1034/J.1600-0560.2003.00113.X

https://onlinelibrary.wiley.com/doi/pdf/10.1034/j.1600-0560.2003.00113.x

13 March 2024

1 reference

https://api.crossref.org/works/10.1034/J.1600-0560.2003.00113.X

Journal of Cutaneous Pathology

13 March 2024

published in

1 reference

8 August 2017

volume

30

1 reference

8 August 2017

issue

9

1 reference

8 August 2017

page(s)

591-595

1 reference

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

Host-vs.-altered-host eruptions in patients on liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

Keratinocyte dysplasia: an usual finding after transplantation or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Pegylation: engineering improved pharmaceuticals for enhanced therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Novel effects with polyethylene glycol modified pharmaceuticals

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Pegylated liposomal doxorubicin: tolerability and toxicity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Mucocutaneous reactions to chemotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Safety aspects of pegylated liposomal doxorubicin in patients with cancer.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Chemotherapy and keratinocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Acute cutaneous eruptions after marrow ablation: roses by other names?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Significance of oral examination in chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0560.2003.00113.X

7 January 2021

Histopathologic reactions to chemotherapeutic agents

16

1 reference

https://api.crossref.org/works/10.1034/J.1600-0560.2003.00113.X

13 March 2024

Identifiers

1 reference

8 August 2017

1 reference